Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
NCCN Guidelines Insights: Breast Cancer, Version 1.2017William J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in OncologyRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
NCCN Guidelines Insights: Breast Cancer, Version 1.2017William J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in OncologyRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Pageof 18